Tobira Development (TBRA) Earning Somewhat Favorable Media Coverage, Analysis Finds
News coverage about Tobira Development (NASDAQ:TBRA) has been trending somewhat positive this week, according to Accern Sentiment. The research firm identifies positive and negative press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Tobira Development earned a media sentiment score of 0.07 on Accern’s scale. Accern also assigned media coverage about the biopharmaceutical company an impact score of 45.9095249556397 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Tobira Development (NASDAQ:TBRA) traded up $0.27 during mid-day trading on Monday, reaching $42.09. The company’s stock had a trading volume of 521,800 shares, compared to its average volume of 251,055. The company has a debt-to-equity ratio of 0.44, a current ratio of 5.38 and a quick ratio of 5.38. Tobira Development has a fifty-two week low of $3.76 and a fifty-two week high of $42.33.
ILLEGAL ACTIVITY WARNING: “Tobira Development (TBRA) Earning Somewhat Favorable Media Coverage, Analysis Finds” was published by Watch List News and is owned by of Watch List News. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. & international copyright legislation. The original version of this news story can be accessed at https://www.watchlistnews.com/tobira-development-tbra-earning-somewhat-favorable-media-coverage-analysis-finds/1771631.html.
About Tobira Development
Tobira Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of therapies for non-alcoholic steatohepatitis (NASH) and other liver diseases. The Company’s product candidate, cenicriviroc (CVC), is a first-in-class immunomodulator and dual inhibitor of C-C chemokine receptor type 2 (CCR2) and C-C chemokine receptor type 5 (CCR5) in late stage development for the treatment of NASH, a serious liver disease that can progress to cirrhosis, liver cancer and liver failure.
Receive News & Ratings for Tobira Development Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tobira Development and related companies with MarketBeat.com's FREE daily email newsletter.